Psychiatric symptoms in children with Fetal Alcohol Spectrum Disorders (FASD) present with high prevalence and morbidity, often across symptom domains, e.g. ADHD-like symptoms, emotional dysregulation and sleep problems. Polypharmacy is often used, but no empirically-based guidelines exist regarding optimal treatment for these children. Moreover, stimulant use in these children is controversial as their responsiveness may be different due to altered neural circuitry associated with prenatal alcohol exposure. The objective of this review is to give an overview of existing data on pharmacological treatments of neurobehavioral symptoms in FASD. Our literature review yielded limited and conflicting clinical data on the effectiveness of pharmacological treatments for psychiatric symptoms in children with FASD, with some symptom domains lacking data altogether. We emphasize the need for clinical trials to guide pharmacological treatments in this complex population.

胎儿酒精谱系障碍 (FASD) 患儿的精神症状具有高患病率和发病率，通常跨越症状领域，例如 ADHD 样症状、情绪失调和睡眠问题。经常使用多种药物，但没有关于这些儿童的最佳治疗的基于经验的指南。此外，这些儿童使用兴奋剂存在争议，因为与产前酒精暴露相关的神经回路发生改变，他们的反应可能不同。本综述的目的是概述 FASD 中神经行为症状的药物治疗的现有数据。我们的文献回顾得出的关于药物治疗对 FASD 儿童精神症状的有效性的临床数据有限且相互矛盾，一些症状域完全缺乏数据。我们强调需要临床试验来指导这一复杂人群的药物治疗。